Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib
[OncoTargets and Therapy] Afatinib, an irreversible ErbB family blocker, may have a potential role as second- or third-line treatment for patients with lung cancer who experience disease progression on an immune checkpoint inhibitor and platinum-based chemotherapy regimen.
